Response to the Letter to the Editor: “Response to Infliximab After Loss of Response to Adalimumab in Crohn’s Disease”.

Response to the Letter to the Editor: “Response to Infliximab After Loss of Response to Adalimumab in Crohn’s Disease”.

Inflamm Bowel Dis. 2019 Nov 21;:

Authors: Casanova MJ, Chaparro M, Gisbert JP

PMID: 31750908 [PubMed – as supplied by publisher]

PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/31750908?dopt=Abstract